



Early View

Original article

Diagnosis of asthma in children: the contribution of a detailed history and test results

Carmen C. M. de Jong, Eva S. L. Pedersen, R. Mozùn, Myrofora Goutaki, Daniel Trachsel, Juerg Barben, Claudia E. Kuehni

Please cite this article as: de Jong CCM, Pedersen ESL, Mozùn R, *et al.* Diagnosis of asthma in children: the contribution of a detailed history and test results. *Eur Respir J* 2019; in press (<https://doi.org/10.1183/13993003.01326-2019>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2019

Diagnosis of asthma in children: the contribution of a detailed history and test results

Carmen CM. de Jong¹, Eva SL. Pedersen¹, R Mozùn¹, Myrofora Goutaki^{1,2}, Daniel Trachsel³, Juerg Barben^{4*}, Claudia E. Kuehni^{1,2*}

Affiliation:

1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
2. Paediatric Respiratory Medicine, Children's University Hospital of Bern, University of Bern, Bern, Switzerland
3. Paediatric Respiratory Medicine, Children's University Hospital of Basel, Basel, Switzerland
4. Paediatric Respiratory Medicine, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland

* These authors contributed equally.

Corresponding author

Claudia E. Kuehni, University of Bern, Institute of Social and Preventive Medicine, Mittelstrasse 43, CH-3012 Bern, Switzerland, claudia.kuehni@ispm.unibe.ch

Take Home Message (177/256 characters): Diagnosing asthma in children is most accurately done by using information on triggers and severity of wheeze and by FeNO measurement, methacholine and exercise challenge tests.

Conflict of interest: None

Funding: Swiss National Science Foundation: 32003B_162820, AstraZeneca (Switzerland), the Lung League St. Gallen and the Schmidheiny Foundation (Heerbrugg, St. Gallen).

Author Contributions: Claudia Kuehni and Juerg Barben conceptualised and designed the study. Daniel Trachsel and Juerg Barben supervised data collection. Carmen de Jong analysed the data and drafted the manuscript. Eva Pedersen and Myrofora Goutaki supported the statistical analysis and gave input for interpretation of the data. All authors critically revised the manuscript and approved the final manuscript as submitted.

Keywords: asthma, wheeze, diagnostic testing, cohort, children, Switzerland

Abstract (236/250)

Introduction: There are little data on the usefulness of different tests to diagnose asthma in children.

Aim: We assessed the contribution of a detailed history and a variety of diagnostic tests for diagnosing asthma in children.

Methods: We studied children aged 6-16 years referred consecutively for evaluation of suspected asthma to two pulmonary outpatient clinics. Symptoms were assessed by parental questionnaire. The clinical evaluation included skin prick tests, measurement of fractional exhaled nitric oxide (FeNO), spirometry, bronchodilator reversibility and bronchial provocation tests (BPT) by exercise, methacholine, and mannitol. Asthma was diagnosed by the physicians at the end of the visit. We assessed diagnostic accuracy of symptoms and tests by calculating sensitivity, specificity, positive and negative predictive values, and area under the curve (AUC).

Results: Of the 111 participants, 80 (72%) were diagnosed with asthma. The combined sensitivity and specificity was highest for reported frequent wheeze (>3 attacks/year) (sensitivity 0.44-specificity 0.90), awakening due to wheeze (0.41-0.90), and wheeze triggered by pollen (0.46-0.83) or by pets (0.29-0.99). Of the diagnostic tests, the AUC was highest for FeNO measurement (0.80) and BPT by methacholine (0.81) or exercise (0.74), and lowest for FEV1 (0.62) and FEV1/FVC (0.66), assessed by spirometry.

Conclusion: This study suggests that specific questions about triggers and severity of wheeze, measurement of FeNO and BPT by methacholine or exercise contribute more to the diagnosis of asthma in school-aged children than spirometry, bronchodilator reversibility and skin prick tests.

Introduction

Diagnosing asthma in children is not straightforward, because we lack a stand-alone diagnostic test.

Symptoms (cough, wheeze, breathlessness) are not specific for asthma and interpretation of commonly used diagnostic tests is complicated by the temporal variability and phenotypic heterogeneity of asthma. Diagnostic guidelines thus suggest diagnosing asthma based on a characteristic pattern of respiratory symptoms, clinical examination, demonstration of reversible airway obstruction assessed by spirometry and airway inflammation measured by FeNO [1-4]. Allergy tests and measurement of bronchial hyperresponsiveness by direct and indirect challenge tests are used as further aids for diagnosis.

However, the diagnostic algorithm proposed by recent guidelines has been questioned for children and there are surprisingly little data available to assess the usefulness of the different tests in the diagnosis of asthma in school-aged children [5]. Systematic literature reviews done for recent guidelines and for the ongoing taskforce of the European Respiratory Society identified only a handful of publications assessing the accuracy of the different tests for children with suspected asthma [2, 3]. Most publications identified by the searches had a case-control design, comparing children with asthma to healthy controls instead of consecutive referrals of children suspected of having asthma. Available studies had included only few diagnostic tests and no detailed history, and asthma diagnosis used as reference standard was often poorly defined or too narrow, for instance including only allergic asthma. Also, papers used different cut-offs for positive tests (e.g. for FeNO or FEV1), and it remains unclear which cut-offs are best for children [1-4]. In this study, we assessed the diagnostic accuracy of reported respiratory symptoms and different objective tests to diagnose asthma in consecutive referrals of school-aged children presenting symptoms suggestive of asthma.

Methods

Study population and study design

For this study, we re-analysed data from a clinical study done in 2007-2008 in Switzerland. It included consecutive first time referrals to the respiratory outpatient clinics of two paediatric hospitals (St. Gallen and Basel) of 6-16 year old children for evaluation of a possible asthma diagnosis with a history of wheezing, dyspnoea or cough. Children were excluded from the study if they had a known chronic respiratory disease such as cystic fibrosis, or a respiratory tract infection during the four weeks prior to the visit. The aim of the initial study had been to compare the results of mannitol challenge tests to exercise challenge tests [6].

Study procedures

All children referred for the first time by general practitioners or primary care paediatricians for evaluation of possible asthma were invited to participate in the study, which included two visits to the hospital within a week (figure 1). At the first visit, all children underwent clinical evaluation, skin prick testing (unless printed results of a skin prick test done during the past 2 years were available), measurement of FeNO, spirometry, exercise BPT, methacholine BPT and bronchodilator reversibility test, in that order. Children who reacted to the exercise challenge and received salbutamol returned for an extra visit within the next few days to perform the methacholine challenge test. Within a week all children repeated the FeNO measurement and performed a mannitol BPT. Between visits, the family completed a questionnaire. Ethical approval was obtained from the local Ethics committee and all parents gave informed consent at baseline (EKSG 07/001).

Clinical asthma diagnosis (reference standard)

The study physicians, experienced paediatric pulmonologists, completed a physician's report form that included the clinical diagnosis (definite asthma, probable asthma or other disease), at two time points. At the first visit, physicians considered only medical history, clinical examination, allergy tests, FeNO

measurement and spirometry. At the second visit, the same physician reported the clinical diagnosis (as definite asthma, probable asthma or other disease) in the second physicians' report form, taking into account all the information available, i.e. medical history, clinical examination, allergy tests, FeNO measurement, spirometry and also results of the bronchial provocation tests and bronchodilator reversibility test. For our main analysis, we defined asthma (reference standard) as an affirmative answer to either definite or probable asthma in the second physician's report form. In a sensitivity analysis, we used the first physicians' report form (based on all the information except the BPTs) to define asthma (reference standard).

Assessment of respiratory symptoms and diagnostic testing

The parental questionnaire included the ISAAC key questions for lower respiratory symptoms and more detailed questions on wheeze and cough derived from the questionnaires used in the Leicester respiratory cohort studies (see supplementary material) [7, 8]. All diagnostic tests were performed according to published guidelines [9-13]. Children withheld short acting beta₂-agonists for 8 hours, inhaled corticosteroids, leukotriene antagonists, and long acting beta₂-agonists for 24 hours, and antihistamines and sodium cromoglycate for >72 hours.

Skin prick test

We performed skin prick tests using birch, grass, mugwort, alternaria, cat, house dust mites (*D. pteronyssinus*), histamine and saline. A wheal size of ≥ 3 mm was considered positive in case the positive control (histamine) had a wheal size of ≥ 3 mm and the negative control (saline) had a wheal size of <3mm. These allergens cover 95% of allergies to inhaled allergens in Switzerland [14].

Fractional exhaled nitric oxide

Fractional exhaled nitric oxide (FeNO) was measured in doublets before spirometry, using the portable multi-gas analyser (NIOX MINO®, Aerocrine, Sweden), in accordance with published guidelines [10] and

previous studies using this device [15, 16]. The portable analyser ensures a constant expiratory flow of 50 ± 5 ml/s, has an accuracy of $\pm 10\%$ with a minimum of ± 5 ppb and the quality was controlled by the lung function technician according to the manufacturer's guidelines.

Spirometry

Spirometry was performed using American Thoracic Society (ATS) criteria for paediatric lung function testing and a Jaeger masterscope (Erich Jaeger GmbH, Würzburg, Germany), using JLAB software (version 4.34). Spirometry was done in triplicate by experienced lung function technicians, who performed quality control during the measurement, and recorded the best measurement. The flow-volume curve was then also checked by the responsible paediatric pulmonologist. Results are expressed as proportion (FEV_1/FVC) and as z-scores based on GLI-2012 reference standards [17].

Bronchial provocation tests

For all bronchial provocation tests, baseline FEV_1 was measured in triplicate using ATS criteria for paediatric lung function testing [9] and the best measurement was recorded. We reported the results of the exercise BPT as the maximum fall of FEV_1 compared to baseline, the methacholine BPT as provocation dose causing a 20% decrease of FEV_1 from baseline (PD20) and the mannitol BPT as provocation dose causing a 15% decrease of FEV_1 from baseline (PD15). After the methacholine BPT, all children were given 4 puffs of salbutamol 100 μ g to test for bronchodilator reversibility. Children also received salbutamol if 15 minutes after the exercise or mannitol BPT, FEV_1 had not returned within 5% of baseline or in case of dyspnoea. More details on the bronchial provocation tests have been published before and can be found in the supplementary material [6].

Statistical analysis

For the reported respiratory symptoms and the different tests, we calculated sensitivity, specificity, positive predictive value and negative predictive value, Youden's Index (sensitivity + specificity -1), area

under the curve (AUC) and their 95% confidence intervals (CI) to diagnose asthma, using the final (post BPT) physicians diagnosis as reference standard. We did a sensitivity analysis using the first (pre BPT) physicians' diagnosis. We displayed the cut-off values with the highest Youden's index in our study and those used in the literature. We used STATA software (version 15; College Station, Texas) for statistical analysis.

Results

Characteristics of the study population

Of the 124 children invited, 111 (90%) were recruited, 84 from St. Gallen and 27 from Basel. The median age was 12 years (range 6-16) and 62% were male. Most children were referred with wheeze and cough (47%) or wheeze without cough (23%). Inhaled medication had been used by 64% prior to referral, including 19% who had used inhaled corticosteroids (table 1). Of the 111 participants, 80 (72%) were diagnosed with asthma after all BPTs were done compared to 94 (85%) before the BPTs were done. The remaining children were diagnosed with cough unrelated to asthma (8% before BPTs and 13% after BPTs), and with inducible laryngeal obstruction and dysfunctional breathing (6% before BPTs and 7% after BPTs) (table S1). None of the children was diagnosed with a severe lung disease such as Cystic Fibrosis [18].

Table 1. Characteristics of the study participants (N=111)

	Total	
	n%	
Age, median (range)	11	(6-16)
Sex, male	69	(62)
Respiratory symptoms in the last 12 months		
Any wheeze	80	(72)
More than 3 attacks of wheeze	38	(34)
Wheeze with colds	43	(39)
Wheeze apart from colds	67	(60)
Exercise-induced wheeze	70	(63)
Wheeze triggered by pollen	36	(32)
Wheeze triggered by house dust	21	(19)
Wheeze triggered by pets	20	(18)
Awakening due to wheeze	36	(32)
Cough longer than 4 weeks	21	(19)
Night cough	48	(43)
Cough more than others	37	(33)
Dyspnoea	25	(23)
Hay fever*	49	(44)
Eczema*	26	(23)
Inhaled medication		
Any	71	(64)
Short-acting B2-agonist, alone	49	(44)
ICS + short-acting B2-agonist	6	(5)
ICS + long-acting B2-agonist	16	(14)

*Ever in the past, ICS = inhaled corticosteroids

Diagnostic accuracy of respiratory symptoms to diagnose asthma

Reported wheeze in the past 12 months had the highest sensitivity (80%) for physician diagnosed asthma (table 2). Specificity was highest for frequent (>3 attacks/year) wheeze (90%), awakening due to wheeze (90%), and wheeze triggered by pollen (83%), house dust (93%) or pets (99%). Combined sensitivity and specificity was highest for frequent wheeze in the past 12 months (Youden's index 0.34), awakening due to wheeze (0.31) and wheeze triggered by pollen (0.29) or pets (0.28) (table 2).

Table 2. Diagnostic accuracy of respiratory symptoms to diagnose asthma N=111

	A+S+ n	A-S+ n	A+S- n	A-S- n	Sens % (95%CI)	Spec % (95%CI)	PPV % (95%CI)	NPV % (95%CI)	YI
Respiratory symptoms in the past 12 months									
Any wheeze	64	16	16	15	80 (70-88)	48 (30-67)	80 (70-88)	48 (30-67)	0.28
> 3 attacks of wheeze	35	3	45	28	44 (33-55)	90 (74-98)	92 (79-98)	38 (27-50)	0.34
Wheeze with colds	32	11	48	20	40 (29-52)	65 (45-81)	74 (59-86)	29 (19-42)	0.05
Wheeze apart from colds	54	13	26	18	68 (56-78)	58 (39-75)	81 (69-89)	41 (26-57)	0.26
Exercise-induced wheeze	54	16	26	15	68 (56-78)	48 (30-67)	77 (66-86)	37 (22-53)	0.16
Wheeze triggered by									
Pollen	31	5	37	24	46 (33-58)	83 (64-94)	86 (71-95)	39 (27-53)	0.29
House dust	19	2	46	26	29 (19-42)	93 (76-99)	90 (70-99)	36 (25-48)	0.22
Pets	20	0	50	17	29 (18-41)	99 (80-99)	99 (83-99)	25 (16-37)	0.28
Awakening due to wheeze	33	3	47	28	41 (30-53)	90 (74-98)	86 (71-95)	37 (26-49)	0.31
Cough > 4 weeks	11	10	68	21	14 (7-24)	68 (49-83)	52 (30-74)	24 (15-34)	-0.18
Night cough	38	10	42	20	48 (36-59)	67 (47-83)	79 (65-90)	32 (21-45)	0.15
Cough more than others	28	9	52	21	35 (25-46)	70 (51-85)	76 (59-88)	29 (19-41)	0.05
Dyspnoea	21	4	58	26	27 (17-38)	87 (69-96)	84 (64-95)	31 (21-42)	0.14
Hay fever*	40	9	38	22	51 (40-63)	71 (52-86)	82 (68-91)	37 (25-50)	0.22
Eczema*	21	5	58	25	27 (17-38)	83 (65-94)	81 (61-93)	30 (21-41)	0.10

A+S+ = children with asthma diagnosis and reported symptom, A-S+ = children without asthma diagnosis but with symptom, A+S- = children with asthma diagnosis but without symptom, A-S- = children without asthma and without symptom, Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative predictive value YI = Youden's-Index = Sensitivity + Specificity -1, *Ever in the past

Diagnostic accuracy of tests to diagnose asthma

All 111 children completed SPT, FeNO, spirometry and BPT by mannitol. BPT by exercise could not be completed in 12 children because of exhaustion (N=7), inspiratory stridor (induced laryngeal obstruction) (N=2), no cooperation (N=2) or technical difficulties (N=1) [6, 19]. Seven patients could not complete BPT by methacholine due to exhaustion and 36 children performed the test during an extra visit a few days later. In four patients the skin prick test result was not considered valid because the histamine control was not positive. Test results in patients with and without asthma diagnosis are displayed in table S2.

The cut-off values with the best diagnostic accuracy were <80% for FEV1/FVC, ≤ -0.8 z-score for FEV1, $\geq 8\%$ decrease of FEV1 for BPT by exercise, PD-20 <0.7mg for BPT by methacholine, PD-15 <635mg for

BPT by mannitol, ≥ 2 for the number of positive skin prick tests, $\geq 8\text{mm}$ for the cumulative wheel size of skin prick tests, and $\geq 21\text{ppb}$ for FeNO (table 3).

Accuracy overall was best for FeNO, BPT by methacholine and BPT by exercise (AUC 0.80, 0.81, 0.74 respectively). Accuracy was lower for BPT by mannitol, and skin prick test (AUC around 0.70), and lowest for spirometry (AUC 0.66 and 0.62 for FEV1 and FEV1/FVC respectively) (figure 2).

Table 3. Diagnostic accuracy of clinical tests to diagnose asthma N=111

	A+T+	A-T+	A+T-	A-T-	Sens	Spec	PPV	NPV	YI	AUC
	n	n	n	n	% (95%CI)	% (95%CI)	% (95%CI)	% (95%CI)		
Clinical tests										
Skin prick test ¹										0.70
≥1 positive test	69	18	8	12	90 (81-95)	40 (23-59)	79 (69-87)	60 (32-81)	0.30	
≥2 positive tests*	61	14	16	16	79 (68-88)	53 (34-72)	81 (71-89)	50 (32-68)	0.32	
Skin prick test ²										0.72
≥4 mm	63	16	12	14	84 (74-91)	47 (28-66)	80 (69-88)	54 (33-73)	0.31	
≥8 mm*	46	7	29	23	61 (49-72)	77 (58-90)	87 (75-95)	44 (30-59)	0.38	
FeNO										0.80
≥21ppb*	47	4	33	27	59 (47-70)	87 (70-96)	92 (81-98)	45 (32-58)	0.46	
≥22ppb	44	4	36	27	55 (43-66)	87 (70-96)	92 (80-98)	43 (30-56)	0.42	
≥25ppb	40	2	40	29	50 (39-61)	94 (79-99)	95 (84-99)	42 (30-55)	0.44	
≥35ppb	31	2	49	29	39 (28-50)	94 (79-99)	94 (80-99)	37 (26-49)	0.33	
Spirometry										
FEV ₁ /FVC										0.66
<70%	6	0	74	30	8 (3-16)	99 (88-99)	99 (54-99)	29 (20-39)	0.08	
<80%*	37	2	43	28	46 (35-58)	93 (78-99)	95 (83-99)	39 (28-52)	0.40	
<90%	66	22	14	8	83 (72-90)	27 (12-46)	75 (65-84)	36 (17-59)	0.09	
FEV ₁										0.62
≤-0.8*	35	7	45	24	44 (33-56)	77 (59-90)	83 (69-93)	35 (24-47)	0.21	
≤-1.0	28	5	52	26	35 (25-47)	84 (66-95)	85 (68-95)	33 (23-45)	0.19	
Bronchodilator rev.										0.58
≥10% increase FEV ₁ *	20	3	54	26	27 (17-39)	90 (73-98)	87 (66-97)	33 (22-44)	0.17	
≥12% increase FEV ₁	16	3	58	26	22 (13-33)	90 (73-98)	84 (60-97)	31 (21-42)	0.11	
BPT										
Exercise										0.74
≥8% decrease FEV ₁ *	47	5	28	19	63 (51-74)	79 (58-93)	90 (79-97)	40 (26-56)	0.42	
≥10% decrease FEV ₁	39	4	36	20	52 (40-64)	83 (63-95)	91 (78-97)	36 (23-50)	0.35	
≥12% decrease FEV ₁	33	2	42	22	44 (33-56)	92 (73-99)	94 (81-99)	34 (23-47)	0.36	
Methacholine										0.81
PD-20 <0.7mg*	62	8	13	21	83 (72-90)	72 (53-87)	89 (79-95)	62 (44-78)	0.55	
PD-20 <1mg	64	9	11	20	85 (75-92)	69 (49-85)	88 (78-94)	65 (45-81)	0.54	
Mannitol										0.68
PD-15 <635 mg*	31	1	49	30	39 (28-50)	97 (83-99)	97 (84-99)	38 (27-50)	0.36	

A+T+ = children with asthma diagnosis and positive test result, A-T+ = children without asthma diagnosis but positive test result, A+T- = children with asthma diagnosis but negative test result, A-T- = children without asthma and negative test result, Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative predictive value, YI = Youden's-Index = Sensitivity + Specificity -1, AUC = area under the curve, FeNO = fractional exhaled nitric oxide, ppb = parts per billion, FEV₁ = forced expiratory volume in 1 second, FVC = forced vital capacity, Bronchodilator rev. = bronchodilator reversibility, BPT = bronchial provocation test

Cut-offs chosen based on proposed cut-offs from previous publications

*Cut-off with maximum combined sensitivity and specificity (highest Youden's-Index)

¹ Number allergens for which the skin prick test is positive: wheel size ≥3

² Cumulative wheel size

Sensitivity analysis

In the sensitivity analysis with asthma diagnosis based on the pre BPTs report form, frequent wheeze and wheeze triggered by pollen or by pets in the past 12 months had the highest Youden's Index, which was in line with the main analysis. Night cough and hay fever also had a high Youden's index for the asthma diagnosis pre BPTs (table S3), but not for the asthma diagnosis post BPTs (table 2).

For the diagnostic tests, the Youden's index was highest at the same cut-offs for most tests (table S4 and Figure S1). Cut-offs were higher for FeNO (25 vs. 21) and lower for BPT by exercise (6 vs. 8), FEV1 (-0.6 vs. -0.8) and bronchodilator reversibility (2 vs. 10).

The accuracy was higher for spirometry (AUC 0.71 and 0.65 versus 0.66 and 0.62 post BPT) and bronchodilator reversibility (AUC 0.72 versus 0.58 post BPT) and lower for the BPTs (AUC 0.70, 0.68 and 0.60 versus 0.74, 0.81 and 0.68 post BPT). Accuracy was best for FeNO measurement, bronchodilator reversibility, FEV1/FVC and BPT by methacholine and by exercise (AUC 0.78, 0.72, 0.71, 0.70, 0.70).

Discussion

This is the first study that systematically assessed the diagnostic accuracy of reported symptoms and a range of tests in asthma diagnosis in children compared to a defined reference standard (doctor diagnosed asthma based on all available measurements and information). The main analysis and sensitivity analysis showed broadly comparable results, suggesting that a history of frequent wheeze, awakening due to wheeze and wheeze triggered by pollen or pets, FeNO measurement, BPT by methacholine and BPT by exercise have the best ability to distinguish asthma from no asthma. FEV1, FEV1/FVC and bronchodilator reversibility had a low accuracy.

Only three other studies assessed the accuracy of symptoms to diagnose asthma in school-aged children consecutively referred to paediatric hospitals [20-22]. They all found that reported wheeze was sensitive (ranging 0.75-0.86) but not specific (0.64-0.73) and that frequent wheeze and awakening due to dyspnoea were specific (0.84-0.90) but not sensitive (0.33-0.54), which is in line with our findings.

Symptom definitions differed between studies, especially those for cough, which results in a wide range of sensitivities and specificities that cannot be compared [20-22]. Five other studies assessed the accuracy of diagnostic tests in school aged children. Woo et al. found that a positive skin prick tests were sensitive but not specific (sensitivity/specificity 0.68/0.32) and that FeNO had the best cut-off at 22 ppb (0.57/0.87), which was comparable with our study (21ppb, 0.59/0.87)) [23]. Grzelewski et al. found that a FEV1/FVC ratio of <80% was specific (0.91), but not sensitive (0.12) for asthma, which is in line with our findings (<79%, 0.90, 0.46) [24]. For the bronchodilator reversibility test, Galant et al. and Dundas et al. found a 9% increase in FEV1 to be the best cut-off to diagnose asthma, which is in line with our finding (10%), however they compared children with asthma to healthy children [25, 26]. For BPT by exercise, Avital et al. found an 8% decrease in FEV1 to be the best cut-off for asthma diagnosis, which is the same as we found [27]. For BPT by methacholine, Zaczeniuk et al. reported a cut off of <0.7 mg as best, which was in line with our study [28]. Anderson et al found a sensitivity of 0.63 and specificity of 0.81 for the widely used best cut off of <635 mg for BPT by mannitol, while we found a lower sensitivity and higher specificity (0.43 and 0.93 respectively) [29].

The recent NICE asthma diagnostic algorithm has been questioned in children. Murray et al. tested the algorithm in the Manchester Asthma and Allergy Study, a population-based cohort of 1184 children aged 13-16 years of which 89 were symptomatic but not regularly inhaling corticosteroids [5]. However, the Manchester study relied on parent-reported data to define asthma (reported wheeze and asthma treatment in the past 12 months plus a doctor diagnosis of asthma ever in life) and compared children with asthma to healthy children, leaving out from the analysis all those with possible asthma. In clinical practice we want to distinguish children with asthma from children with respiratory symptoms due to other causes, not from healthy children. If we would have applied the NICE algorithm to our clinical population, only 4 of the 111 children would have been diagnosed with asthma at the initial visit (FEV1/FVC <70% and bronchodilator responsibility of $\geq 12\%$). 106 would have needed 2 weeks peak expiratory flow monitoring followed by a second visit. We also found that less stringent cut off values

had higher sensitivity and specificity than those recommended by the NICE algorithm (FEV1/FVC <80% vs. <70%, bronchodilator reversibility $\geq 10\%$ vs. $\geq 12\%$ and FeNO ≥ 26 ppb vs. ≥ 35 ppb, respectively). This highlights the need to base diagnostic algorithms for children on clinical studies done in children, rather than in adults.

A main strength of our study is that it represents a real-life situation in everyday paediatric practice. With this clinical design, it reflects the typical mix of patients in a paediatric outpatient clinic. All children were first-time referrals for evaluation of possible asthma, which is the patient group diagnostic tests are intended for. Therefore, the study population is representative of daily clinical practice, in contrast to many published studies that selectively include well-defined moderate to severe asthmatics comparing them to healthy controls and excluding patients with unclear degrees of airway reactivity. In addition, our patients had an extensive array of examinations for lung function, BPT and allergy, which allowed us to assess the accuracy of different symptoms and diagnostic tests simultaneously.

An important limitation of this study was that the reference standard for asthma diagnosis (the final diagnosis by the physician) took into account the results of the patient history and diagnostic tests for which the accuracy was assessed. However, as there is no single objective test to diagnose asthma and be used as a comparator, the clinician's judgement, taking into account the full history, examination and test results, is the best we can do. The sensitivity analysis using the physicians' diagnosis before BPTs were performed, showed comparable results. The small differences, however, highlight the dependence of the physician's diagnosis on the array of tests done. The reference diagnosis of asthma was made by experienced paediatric pulmonologists (3 in Basel and 2 in St. Gallen), trained in Switzerland, who met several times prior to and during the study to standardise their procedures and minimise centre specific effects. In this study we restricted analysis to basic clinical tests. The advantage of this approach is that most of these tests are available in clinical routine. However, future studies should also evaluate the

diagnostic accuracy of newer techniques such as component-resolved IgE diagnostic, multiple breath or single-breath washout techniques.

Our findings, which need to be replicated in other populations of patients, will help to propose a more evidence based paediatric diagnostic algorithm, which incorporates both information on symptoms and objective measures. This might be helpful in reducing the need for trials of asthma treatment, which can be costly, time consuming and can lead to misdiagnosis and overtreatment. Our study is therefore an important contribution to the small body of evidence about the value of different tests for the diagnosis of paediatric asthma on which guidelines should be based. Mild paediatric asthma is a disease with highly variable activity and paroxysmal clinical manifestation. It seems unlikely that any test performed at a specific time point will be accurate enough to either prove or exclude reactive airway disease.

Future studies should ideally be larger, to allow analysing the value of combination of several tests, and focus on children newly referred for evaluation of possible asthma, and be referenced to a clearly defined and robust reference diagnosis.

Our results suggest that, until more evidence is available, diagnosis of asthma in school aged children should rely primarily on reported triggers and severity of wheeze and results of FeNO, and if available methacholine and exercise challenge testing which were most accurate in our study.

Acknowledgements

We thank all participants and lab technicians of the pulmonology department in the children's hospitals in Basel and St. Gallen for their assistance in our study, Marie-Pierre Strippoli (ISPM, Bern) for her work on the study at baseline. We thank Christopher Ritter (ISPM, Bern) for his editorial assistance.

References

1. GINA. Global strategy for asthma management and prevention. <https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf>. Date last updated: 2018. Date last accessed: June 2019
2. BTS-SIGN. British guideline on the management of asthma. <https://www.sign.ac.uk/assets/sign153.pdf>. Date last updated: September 2016. Date last accessed: June 2019.
3. NICE. Guideline asthma diagnosis and monitoring <https://www.nice.org.uk/guidance/ng80/evidence/full-guideline-asthma-diagnosis-and-monitoring-pdf-4656178047>. Date last updated: November 2017. Date last accessed: June 2019.
4. NIH EPR3. Guidelines for diagnosis and management of asthma. <https://www.nlm.nih.gov/sites/default/files/media/docs/asthsumm.pdf>. Date last updated: October 2007. Date last accessed: June 2019
5. Murray C, Foden P, Lowe L, Durrington H, Custovic A, Simpson A. Diagnosis of asthma in symptomatic children based on measures of lung function: an analysis of data from a population-based birth cohort study. *Lancet Child Adolesc Health* 2017; 1(2): 114-123.
6. Barben J, Kuehni CE, Strippoli MP, Schiller B, Hammer J, Trachsel D, Swiss Paediatric Respiratory Research Group. Mannitol dry powder challenge in comparison with exercise testing in children. *Pediatr Pulmonol*. 2011;46:842–848.
7. Kuehni CE, Brooke AM, Strippoli MP, Spycher BD, Davis A, Silverman M. Cohort profile: the Leicester respiratory cohorts. *Int J Epidemiol* 2007; 36(5): 977-985.
8. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, Mitchell EA, Pearce N, Sibbald B, Stewart AW, et al. International study of asthma and allergies in childhood (ISAAC): rationale and methods. *Eur Respir J*. 1995;8:483-491.
9. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med*. 1995;152(3):1107-1136.
10. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med*. 1999;160(6):2104-2117.
11. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, et al. Guidelines for methacholine and exercise challenge testing-1999. *Am J Respir Crit Care Med*. 2000;161(1):309-329.
12. Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, Gonda I, Walsh A, Clark AR. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. *Am J Respir Crit Care Med*. 1997;156(3.1):758-765.
13. Barben J RJ. Measurement of bronchial responsiveness in children. In: Hammer J, Eber E, editors. *Paediatric pulmonary function testing*. Prog Respir Res. Basel: Karger;2005;33:125-136.
14. Braun-Fahrlander C, Wüthrich B, Gassner M, Gritze I, Neu U, Varonier H. Prävalenz und Risikofaktoren einer allergischen Sensibilisierung bei Schulkindern in der Schweiz. *Allergologie*. 1999;22:54-64.
15. Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: Comparison with the "gold standard" technique. *Chest*. 2007; 131(2): 410-414.
16. Schiller B, Hammer J, Barben J, Trachsel D. Comparability of a hand-held nitric oxide analyser with online and offline chemiluminescence-based nitric oxide measurement. *Pediatr Allergy Immunol*. 2009; 20(7): 679-685.
17. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012; 40(6): 1324-1343.

18. de Jong CCM, Pedersen ES, Goutaki M, Trachsel D, J. B, Kuehni CE. Do clinical investigations predict long-term wheeze? A follow-up of pediatric respiratory outpatients. *Pediatric Pulmonology* 2019; 54(8): 1156-1161.
19. Barben J, Strippoli MP, Trachsel D, Schiller B, Hammer J, Kuehni CE. Effect of Mannitol dry powder challenge on exhaled nitric oxide in children. *PLoS One*. 2013;8(1):e54521.
20. Ma TT, Zhuang Y, Gong HY, Yii AC, Wang XY, Shi HZ. Predictive value of respiratory symptoms for the diagnosis of pollen-induced seasonal asthma among children and adults in Inner Mongolia. *Ther Clin Risk Manag*. 2017; 13: 967-974.
21. Brouwer AF, Visser CA, Duiverman EJ, Roorda RJ, Brand PL. Is home spirometry useful in diagnosing asthma in children with nonspecific respiratory symptoms? *Pediatr Pulmonol*. 2010; 45(4): 326-332.
22. Crispino Santos MC ACA. A brief questionnaire for screening asthma among children and adolescents in Rio de Janeiro, Brazil. *Allergol Immunopathol*. 2005; 33(1): 20-26.
23. Woo SI, Lee JH, Kim H, Kang JW, Sun YH, Hahn YS. Utility of fractional exhaled nitric oxide (F(E)NO) measurements in diagnosing asthma. *Respir Med*. 2012; 106(8): 1103-1109.
24. Grzelewski T, Witkowski K, Makandjou-Ola E, Grzelewska A, Majak P, Jerzynska J, Janas A, Stelmach R, Stelmach W, Stelmach I. Diagnostic value of lung function parameters and FeNO for asthma in schoolchildren in large, real-life population. *Pediatr Pulmonol*. 2014; 49(7): 632-640.
25. Galant SP, Morphew T, Amaro S, Liao O. Value of the bronchodilator response in assessing controller naive asthmatic children. *J Pediatr* 2007; 151(5): 457-462.
26. Dundas I, Chan EY, Bridge PD, McKenzie SA. Diagnostic accuracy of bronchodilator responsiveness in wheezy children. *Thorax* 2005; 60(1): 13-16.
27. Avital A, Godfrey S, Springer C. Exercise, methacholine, and adenosine 5'-monophosphate challenges in children with asthma: relation to severity of the disease. *Pediatr Pulmonol*. 2000; 30(3): 207-214.
28. Zaczeniuk M, Woicka-Kolejwa K, Stelmach W, Podlecka D, Jerzynska J, Stelmach I. Methacholine challenge testing is superior to the exercise challenge for detecting asthma in children. *Ann Allergy Asthma Immunol*. 2015; 115(6): 481-484.
29. Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, Pearlman DS. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. *Respir Res*. 2009; 10: 4.





Figure 1. Study procedures. The report form is a standardised form for physicians to note down the clinical diagnosis. BPT: bronchial provocation test. Bronchodilator rev.: Bronchodilator reversibility. *Children who received salbutamol after the exercise BPT conducted the methacholine BPT at an extra visit.  Between visits the family completed a questionnaire.




Figure 2 Receiver operating characteristics (ROC) curve of clinical tests to diagnose asthma.

* Cut-off with maximum combined sensitivity and specificity

Test	Unit
SPT number positive	decrease of 1 positive skin prick test
SPT cumulative wheel size	decrease of 1 mm cumulative wheel size
FeNO	decrease of 1 parts per billion (ppb)
FEV1	increase of 0.1 z-score
FEV1/FVC	increase of 1%
Bronchodilator reversibility	increase of 1% in FEV ₁
Exercise	decrease of 1% in FEV ₁
Methacholine	increase of 0.1 mg methacholine
Mannitol	increase of 5 mg mannitol

Supplementary text:

Methods of bronchial provocation tests

For all bronchial provocation tests, baseline FEV₁ was measured in triplicate using ATS criteria for paediatric lung function testing [1] and the best measurement was recorded. Children were excluded from the challenge if their baseline FEV₁ was ≤65% of predicted or if they were unwilling to cooperate. If 15 minutes after the bronchial provocation test, FEV₁ had not returned within 5% of baseline or in case of dyspnoea, salbutamol 100 µg (2-4 puffs Ventolin® pMDI via spacer) was given to reverse the bronchoconstriction.

Exercise provocation test

The children performed the exercise challenge using a treadmill (T-2100, GE Healthcare, Freiburg, Germany) or a bicycle ergometer (ER Ergoselect 200, Ergoline GmbH, Bitz, Germany) for 8 min, inspiring room air according to published ATS and ERS guidelines [2, 3]. At one site, children chose between treadmill and bicycle, at the other only a treadmill was available. We performed exercise testing under controlled conditions (maintaining inspired air temperature at 20–25°C and humidity of <10 mg water/L) [4] and measured heart rate and oxygen saturation by pulse oximeter with a forehead sensor (Nellcor N595 OxiMax, Tyco Healthcare, Neustadt/Donau, Germany). After baseline spirometry we started exercise testing at 60% target workload (defined as Watt = measured FEV₁ x 53.76-11.07), rapidly increasing workload aiming at 75% of the target in the second minute, 90% in the third minute, and 100% in the fourth minute, sustaining the latter for ≥4 min. We increased workloads more rapidly if the heart rate was not expected to reach at least 85% of the predicted maximum (220-age in years). [2] Spirometry was performed 1, 3, 5, 7, 10, and 15 min after exercise, in duplicate [5].

We reported the results as the maximum fall of FEV₁ during the exercise provocation test.

Methacholine provocation test

The children performed the methacholine provocation test based on the Five-Breath Dosimeter Protocol [2, 4]. They first inhaled NaCl 0.9% to measure baseline values, then they inhaled stepwise 0.05mg, 0.05mg, 0.2mg, 0.3mg, 0.6mg and 1.2mg of methacholine (cumulative dose of 2.4 mg in children <14 years old) via a nebulizer. Children older than 14 years old had an additional inhalation step with a cumulative dose of 3.2mg methacholine. At end exhalation during tidal breathing, the children inhaled slowly and deeply from the nebulizer. The dosimeter was triggered after the inhalation begins, and the subject was encouraged to continue inhaling slowly and to hold the breath for another 5 seconds. This step was repeated for a total of five inspiratory capacity inhalations which should not take more than 2 minutes. The challenge was terminated when FEV₁ fell by 20% or more, or the highest dose was given. Lung function was measured in 5-min intervals until it had returned to within 5% of the baseline value. We reported the results of the methacholine provocation test as provocation dose causing a 20% decrease of FEV₁ from baseline (PD-20).

Mannitol dry powder provocation test

The mannitol provocation test was performed according to the protocol recommended by Anderson et al. [6], with slight modifications [7, 8]. Baseline FEV₁ was measured in triplicate and the highest of these measures was recorded. The mannitol dry powder (MDP) provocation test (Aridol™, Pharmaxis, French Forests, New South Wales, Australia) was conducted as described in our previous study [8]. The children were asked to inhale the

contents of an MDP capsule through the delivery device (OsmohalerTM). The following dosing steps were used: 0 mg (empty capsule acting as a placebo to measure baseline FEV₁), 5, 10, 20, 40, 80, 160, 160, and 160 mg. We administered multiples of 40 mg capsules to achieve doses of 80 mg and more. After each dose, children performed a 5-sec breath-hold, followed one minute later by spirometry in duplicate, and the higher FEV₁ was recorded. If the children had a decrease in FEV₁ >10%, then the dose producing this was repeated for safety reasons. This process was repeated until either FEV₁ had fallen by 15% or the subject had reached the maximum dose (cumulative dose of 635 mg mannitol). We reported the results of the mannitol provocation test as provocation dose causing a 15% decrease of FEV₁ from baseline (PD-15).

References

1. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med.* 1995;152(3):1107-1136.
2. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, et al. Guidelines for methacholine and exercise challenge testing-1999. *Am J Respir Crit Care Med.* 2000;161(1):309-329.
3. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, Juniper EF, Malo JL. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J.* 1993; 16: 53-83.
4. Barben J RJ. Measurement of bronchial responsiveness in children. In: Hammer J, Eber E, editors. *Paediatric pulmonary function testing.* Prog Respir Res. Basel: Karger;2005;33:125-136.
5. Riedler J. Nonpharmacological challenges in the assessment of bronchial responsiveness. *Eur Respir Mon.* 1997; 5: 115-135.
6. Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, Gonda I, Walsh A, Clark AR. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. *Am J Respir Crit Care Med.* 1997;156(3.1):758-765.
7. Barben J, Roberts M, Chew N, Carlin JB, Robertson CF. Repeatability of bronchial responsiveness to mannitol dry powder in children with asthma. *Pediatr Pulmonol.* 2003; 36(6): 490-494.
8. Barben J, Kuehni CE, Strippoli MP, Schiller B, Hammer J, Trachsel D, Swiss Paediatric Respiratory Research Group. Mannitol dry powder challenge in comparison with exercise testing in children. *Pediatr Pulmonol.* 2011;46:842-848.

Supplementary tables and figure

Table S1. Diagnoses in children with suspected asthma N=111

	Diagnoses pre-BPTs ¹		Diagnoses post-BPTs ¹	
	n (%)		n (%)	
Definite diagnoses	79	(71)	97	(87)
Asthma	65	(59)	68	(61)
Cough not due to asthma	9	(8)	14	(13)
ILO ² /vocal cord dysfunction	3	(3)	6	(5)
Functional symptoms / hyperventilation	0	(0)	7	(6)
Adenoid hyperplasia with OSAS ³	1	(1)	1	(1)
Recurrent colds	1	(1)	1	(1)
Probable diagnoses	32	(29)	14	(13)
Asthma	29	(26)	12	(11)
ILO ² /vocal cord dysfunction	3	(3)	2	(2)

¹ Bronchial Provocation Tests

² Inducible Laryngeal Obstruction

³ Obstructive Sleep Apnoea Syndrome

Table S2. Diagnostic test results in patients with and without asthma N=111

Diagnostic tests	Asthma					
	Definite asthma N=68 median (IQR)		Other diagnosis N=31 median (IQR)		Probable asthma N=12 median (IQR)	
Skin prick test (N=107)						
≥1 positive test n(%)	29	(43)	7	(23)	5	(42)
Number of positive tests*	3	(2-4)	2	(0-3)	2	(1-3)
Cum wheel size in mm±	9	(5-14)	5	(0-8)	7	(0-9)
FeNO (N=111)						
Parts per billion	30	(14-62)	10	(6-16)	14	(9-22)
Spirometry (N=111)						
FEV1, z-scores	-0.5	(-1.2-0.3)	-0.1	(-0.5-0.4)	-1.0	(-2.2--0.2)
FEV1/FVC	83	(75-89)	87	(83-90)	78	(71-89)
Bronchodilator rev. (N=103)						
Increase in FEV1 in %	4	(-5-14)	1	(-5-8)	3	(-1-6)
Bronchial provocation test						
Exercise (N=99)						
Decrease in FEV1 in %°	12	(6-19)	4	(1-7)	5	(1-6)
Methacholine (N=104)						
Provocation dose in mg“	0.1	(0.1-0.3)	2.4	(0.3-3.2)	0.3	(0.1-1.6)
Mannitol (N=111)						
Provocation dose in mg#	635	(190-635)	635	(635-635)	635	(635-635)

° median (and inter quartile range) fall in FEV1 during exercise

“ median (and inter quartile range) provocation dose for a fall of ≥ 20% in FEV1 (PD-20)

median (and inter quartile range) provocation dose for a fall of ≥ 15% in FEV1 (PD-15)

* Wheal size ≥3mm

± Cumulative wheel size in mm

Bronchodilator rev. = Bronchodilator reversibility

Table S3. Sensitivity analysis of diagnostic accuracy of respiratory symptoms to diagnose asthma pre-BPTs N=111

	A+S+ n	A-S+ n	A+S- n	A-S- n	Sens % (95%CI)	Spec % (95%CI)	PPV % (95%CI)	NPV % (95%CI)	YI
Respiratory symptoms in the past 12 months									
Any wheeze	69	11	25	6	73 (63-82)	35 (14-62)	86 (77-93)	19 (7-37)	0.08
> 3 attacks of wheeze	36	2	58	15	38 (28-49)	88 (64-99)	95 (82-99)	21 (12-32)	0.26
Wheeze with colds	36	7	58	10	38 (28-49)	59 (33-82)	84 (69-93)	15 (7-25)	-0.03
Wheeze apart from colds	59	8	35	9	63 (52-73)	53 (28-77)	88 (78-95)	20 (10-35)	0.16
Exercise-induced wheeze	62	8	32	9	66 (55-75)	53 (28-77)	89 (79-95)	22 (11-38)	0.19
Wheeze triggered by									
Pollen	34	2	47	14	42 (31-53)	88 (62-98)	94 (81-99)	23 (13-35)	0.30
House dust	20	1	58	14	26 (16-37)	93 (68-99)	95 (76-99)	19 (11-30)	0.19
Pets	20	0	57	10	26 (17-37)	99 (69-99)	99 (83-99)	15 (7-26)	0.25
Awakening due to wheeze	33	3	61	14	35 (26-46)	82 (57-96)	92 (78-98)	19 (11-29)	0.17
Cough > 4 weeks	14	7	79	10	15 (8-24)	59 (33-82)	67 (43-85)	11 (6-20)	-0.26
Night cough	45	3	49	13	48 (37-58)	81 (54-96)	94 (83-99)	21 (12-33)	0.29
Cough more than others	32	5	61	12	34 (25-45)	71 (44-90)	86 (71-95)	16 (9-27)	0.05
Dyspnoea	23	2	69	15	25 (17-35)	88 (64-99)	92 (74-99)	18 (10-28)	0.13
Hay fever	46	3	46	14	50 (39-61)	82 (57-96)	94 (83-99)	23 (13-36)	0.32
Eczema	24	2	68	15	26 (17-36)	88 (64-99)	92 (75-99)	18 (10-28)	0.14

A+S+ = children with asthma diagnosis and reported symptom, A-S+ = children without asthma diagnosis but with symptom, A+S- = children with asthma diagnosis but without symptom, A-S- = children without asthma and without symptom, Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative predictive value YI = Youden's-Index = Sensitivity + Specificity -1

Table S4. Sensitivity analysis of diagnostic accuracy of clinical tests to diagnose asthma pre BPTs
N=111

	A+T+ n	A-T+ n	A+T- n	A-T- n	Sens % (95%CI)	Spec % (95%CI)	PPV % (95%CI)	NPV % (95%CI)	YI	AUC
Clinical tests										
Skin prick test ¹										0.69
≥1 positive test	79	8	12	8	87 (78-93)	50 (25-75)	91 (83-96)	40 (19-64)	0.37	
≥2 positive tests*	70	5	21	11	77 (67-85)	69 (41-89)	93 (85-98)	34 (19-53)	0.46	
Skin prick test ²										0.69
≥4 mm*	73	6	16	10	82 (72-89)	63 (35-85)	92 (84-97)	38 (20-59)	0.45	
≥8 mm	49	4	40	12	55 (44-66)	75 (48-93)	92 (82-98)	23 (13-37)	0.30	
FeNO										0.78
≥21ppb	49	2	45	15	52 (42-63)	88 (64-99)	96 (87-99)	25 (15-38)	0.40	
≥22ppb	46	2	48	15	49 (38-59)	88 (64-99)	96 (86-99)	24 (14-36)	0.37	
≥25ppb*	42	0	52	17	45 (34-55)	99 (80-99)	99 (91-99)	25 (15-36)	0.44	
≥35ppb	33	0	61	17	35 (26-46)	99 (80-99)	99 (89-99)	22 (13-33)	0.34	
Spirometry										
FEV1/FVC										0.71
<70%	6	0	88	16	6 (2-13)	99 (79-99)	99 (54-99)	15 (9-24)	0.06	
<80%	39	0	55	16	41 (31-52)	99 (79-99)	99 (91-99)	23 (13-34)	0.41	
<81%*	40	0	54	16	43 (32-53)	99 (79-99)	99 (91-99)	23 (14-34)	0.43	
<90%	77	11	17	5	82 (73-89)	31 (11-59)	88 (79-94)	23 (8-45)	0.13	
FEV1										0.65
≤0.6*	45	2	49	15	48 (38-58)	88 (64-99)	98 (85-99)	23 (14-36)	0.36	
≤0.8	40	2	54	15	43 (32-53)	88 (64-99)	95 (84-99)	22 (13-33)	0.31	
≤1.0	31	2	63	15	33 (24-43)	88 (64-99)	94 (80-99)	19 (11-30)	0.21	
Bronchodilator rev.										0.72
≥2% increase FEV ₁ *	55	3	32	13	63 (52-73)	81 (54-96)	95 (86-99)	29 (16-44)	0.44	
≥10% increase FEV ₁	23	0	64	16	26 (18-37)	99 (79-99)	99 (85-99)	20 (12-30)	0.26	
≥12% increase FEV ₁	19	0	68	16	22 (14-32)	99 (79-99)	99 (82-99)	19 (11-29)	0.22	
BPT										
Exercise										0.70
≥6% decrease FEV ₁ *	57	3	29	10	66 (55-76)	77 (46-95)	95 (86-99)	26 (13-42)	0.43	
≥8% decrease FEV ₁	49	3	37	10	57 (46-68)	77 (46-95)	94 (84-99)	21 (11-36)	0.34	
≥10% decrease FEV ₁	40	3	46	10	47 (36-58)	77 (46-95)	93 (81-99)	18 (9-30)	0.24	
≥12% decrease FEV ₁	32	3	54	10	37 (27-48)	77 (46-95)	91 (77-98)	16 (8-27)	0.14	
Methacholine										0.68
PD-20 <0.6mg*	65	5	23	11	74 (63-83)	69 (41-89)	93 (84-98)	32 (17-51)		
PD-20 <0.7mg	67	6	21	10	76 (66-85)	63 (35-85)	92 (83-97)	32 (17-51)	0.43	
PD-20 <1mg	67	6	21	10	76 (66-85)	63 (35-85)	92 (83-97)	32 (17-51)	0.39	
Mannitol										0.60
PD-15 <635 mg*	30	2	64	15	32 (23-42)	88 (64-99)	94 (79-99)	19 (11-29)	0.20	

A+T+ = children with asthma diagnosis and positive test result, A-T+ = children without asthma diagnosis but positive test result, A+T- = children with asthma diagnosis but negative test result, A-T- = children without asthma and negative test result, Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative predictive value, YI = Youden's-Index = Sensitivity + Specificity -1, AUC = area under the curve, FeNO = fractional exhaled nitric oxide, ppb = parts per billion, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, Bronchodilator rev. = bronchodilator reversibility, BPT = bronchial provocation test

Cut-offs chosen based on proposed cut-offs from previous publications

*Cut-off with maximum combined sensitivity and specificity (highest Youden's-Index)

¹ Number allergens for which the skin prick test is positive: wheel size ≥3

² Cumulative wheel size




Figure S1 Receiver operating characteristics (ROC) curve of clinical tests to diagnose asthma. (Sensitivity analysis: pre-BPTs) * Cut-off with maximum combined sensitivity and specificity

Test	Unit
SPT number positive	decrease of 1 positive skin prick test
SPT cumulative wheel size	decrease of 1 mm cumulative wheel size
FeNO	decrease of 1 parts per billion (ppb)
FEV1	increase of 0.1 z-score
FEV1/FVC	increase of 1%
Bronchodilator reversibility	increase of 1% in FEV ₁
Exercise	decrease of 1% in FEV ₁
Methacholine	increase of 0.1 mg methacholine
Mannitol	increase of 5 mg mannitol

Supplementary questionnaire 2

Baseline questionnaire, English translation

Questionnaire on breathing and allergies

How to fill it in? yes ☐ no ☐ = please, tick the appropriate box

|15 |10 |1998| = please, fill out

_____ = please, write words

General questions

Date questionnaire completed:
day month year

Person completing questionnaire: mother ☐ father ☐ child ☐ other ☐ _____
(tick all who helped to fill in)

Last name _____
First name _____
Birthdate |__| |__| |__| | Sex male ☐ female ☐
 day month year

Part 1

1. In the last 12 months, how many times have you had a cold or flu?

None ☐ 1-3 ☐ 4-6 ☐ 7-9 ☐ 10 or more ☐

2. How long does a cold usually last?

Less than a week ☐ 1-2 weeks ☐ 2-4 weeks ☐ More than 4 weeks ☐

3. In the last 12 months, have you had a cough that lasted more than 4 weeks?

yes ☐ no ☐

4. In the last 12 months, have you had a dry cough at night, apart from a cough associated with a cold or a chest infection?

yes ☐ no ☐

5. Do you think that you cough more than other children your age?

yes ☐ no ☐

Part 2

6. Have you ever had wheezing or whistling in the chest at any time in the past?

yes ☐ no ☐

7. Have you had wheezing or whistling in the chest in the last 12 months?

yes ☐ no ☐

If you answered “no” to both questions, please skip to part 3.

8. How many attacks of wheezing have you had during the last 12 months?

None ☐ 1-3 times ☐ 4-12 times ☐ More than 12 times ☐

9. In the last 12 months, have you had wheezing or whistling in the chest during or soon after a cold or flu?

yes ☐

no ☐

10. In the last 12 months, have you had wheezing or whistling in the chest without having a cold or flu?

yes ☐

no ☐

11. In the last 12 months, has your chest sounded wheezy during or after exercise?

yes ☐

no ☐

12. In the last 12 months, which of the following things caused you to wheeze

- | | | | |
|---------------------------------------|------------------------------|-----------------------------|-------------------------------------|
| - Exercise (running, sports) | yes <input type="checkbox"/> | no <input type="checkbox"/> | Don't know <input type="checkbox"/> |
| - Laughing or crying | yes <input type="checkbox"/> | no <input type="checkbox"/> | Don't know <input type="checkbox"/> |
| - Pollen (grass, hay, trees, flowers) | yes <input type="checkbox"/> | no <input type="checkbox"/> | Don't know <input type="checkbox"/> |
| - House dust | yes <input type="checkbox"/> | no <input type="checkbox"/> | Don't know <input type="checkbox"/> |
| - Contact with pets or other animals | yes <input type="checkbox"/> | no <input type="checkbox"/> | Don't know <input type="checkbox"/> |
| - Foods or drinks | yes <input type="checkbox"/> | no <input type="checkbox"/> | Don't know <input type="checkbox"/> |

13. In the last 12 months, how often, on average, has your sleep been disturbed due to wheezing?

Never woken up ☐

Less than one night per week ☐

One or more nights per week ☐

14. In the last 12 months, has wheezing ever been severe enough to limit your speech to only one or two words at a time between breaths?

yes ☐

no ☐

15. Have you ever had asthma?

yes ☐

no ☐

16. Do you need to use medication because of these breathing problems?

yes ☐

no ☐

- If yes, how regularly?

Sometimes (less than once per week) ☐

Regularly (1-6 times per week) ☐

Daily ☐

- If yes, which medication?

17. In the last 12 months, how much did cough, wheezing or breathlessness interfere with your daily activities (at home or while playing with other kids)

Practically daily ☐

About once a week ☐

About once per month ☐

Less than once per month ☐

Never ☐

Don't know ☐

18. In the last 12 months, how much did cough, wheezing or breathlessness interfere with your sport activities?

Practically daily ☐

About once a week ☐

About once per month ☐

Less than once per month ☐

Never ☐

Don't know ☐

Part 3

19. In the last 12 months, have you had a problem with sneezing or a runny or blocked nose when you did not have a cold or flu?

yes ☐

no ☐

20. In the last 12 months, has this nose problem been accompanied by itchy-watery eyes?

yes ☐

no ☐

21. In which of the last 12 months, did these problems occur?

January ☐

February ☐

March ☐

April ☐

May ☐

June ☐

July ☐

August ☐

September ☐

October ☐

November ☐

December ☐

22. In the last 12 months, how much did these problems interfere with your daily activities?

Not at all ☐

A little ☐

Moderately ☐

Very much ☐

23. Have you ever had hay fever?

yes ☐

no ☐

Part 4

24. Have you ever had an itchy rash, which was coming and going for at least six months?

yes ☐

no ☐

25. Have you had this itchy rash at any time in the last 12 months?

yes ☐

no ☐

26. Has this itchy rash affected any of the following places: the folds of the elbows, behind the knees or around the neck, ears or eyes?

yes ☐

no ☐

-If yes, which places were affected by this itchy rash? _____

27. Has this rash cleared completely at any time during the last 12 months?

yes ☐

no ☐

28. In the last 12 months, how often, on average, have you been kept awake at night by this itchy rash?

Never in the last 12 months ☐

Less than 1 night per week ☐

One or more nights per week ☐

29. Have you ever had eczema?

yes ☐

no ☐

Part 5

30. Did you ever have problems with your heart?

yes ☐

no ☐

31. What kind of heart problems?

Arrhythmia ☐

Congenital heart defect ☐

Other ☐ _____

32. Did you ever have to take medication for your heart?

yes ☐

no ☐

33. Did you ever have a heart surgery?

yes ☐

no ☐

34. Do your heart problems still interfere with your daily activities?

yes ☐

no ☐

Part 6

35. Who smokes in your household?

Father	yes <input type="checkbox"/>	no <input type="checkbox"/>
Mother	yes <input type="checkbox"/>	no <input type="checkbox"/>
Other adult	yes <input type="checkbox"/>	no <input type="checkbox"/>
Children	yes <input type="checkbox"/>	no <input type="checkbox"/>

36. How many cigarettes in total are being smoked in your house per day?

None ☐

1-10 ☐

11-20 ☐

21-40 ☐

Über 40 ☐

37. Do you smoke yourself?

Yes, I smoke sometimes ☐

Yes, I have tried it once or twice,
but I don't smoke regularly ☐

No, I have never smoked ☐

- If yes, how many packages do you smoke per week? _____

- If yes, since how many months do you smoke? _____

Comment box

Thank you for completing the questionnaire!